Study for the Treatment of Myelodysplastic Syndrome With Different Proportions of Qinghuang Powder

TRIF Signaling Pathway in Different Ratio of Qinghuang Powder on the Treatment of Myelodysplastic Syndrome of Curative Effect Prediction and Regulation Mechanism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026032

Enrollment

Unknown

Registered

2019-09-18

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic syndrome

Interventions

High Dose Qinghuang Powder Group:Take 2 capsule of Qinghuangsan once a day

Low Dose Qinghuang Powder Group:Take 1 capsule of Qinghuangsan once a day

Eligibility

Sex/Gender

All

Age

16 Years to 75 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for myelodysplastic syndrome; aged 16 to 75 years; volunteered subjects, and signed informed consent.

Exclusion criteria

Exclusion criteria: Patients with severe side effects during medication; patients known to be allergic to the drug; pregnant and lactating women; psychiatric patients; combined with serious heart, liver and kidney complications; participated in other clinical studies.

Design outcomes

Primary

Measure	Time frame
Routine blood test;signaling pathway related genes and effectors;	—

Countries

China

Contacts

Public ContactTang Xudong

Department of Hematology, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

tangxudong001@163.com+86 13520016513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026